GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioject Medical Technologies Inc (OTCPK:BJCT) » Definitions » ROC (Joel Greenblatt) %

BJCT (Bioject Medical Technologies) ROC (Joel Greenblatt) % : 368.42% (As of Sep. 2011)


View and export this data going back to . Start your Free Trial

What is Bioject Medical Technologies ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Bioject Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2011 was 368.42%.

The historical rank and industry rank for Bioject Medical Technologies's ROC (Joel Greenblatt) % or its related term are showing as below:

BJCT's ROC (Joel Greenblatt) % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -1.44
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Bioject Medical Technologies's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Bioject Medical Technologies ROC (Joel Greenblatt) % Historical Data

The historical data trend for Bioject Medical Technologies's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioject Medical Technologies ROC (Joel Greenblatt) % Chart

Bioject Medical Technologies Annual Data
Trend Mar01 Mar02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -139.51 -146.75 -127.85 -65.99 -196.85

Bioject Medical Technologies Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -168.45 -147.55 -102.00 214.16 368.42

Competitive Comparison of Bioject Medical Technologies's ROC (Joel Greenblatt) %

For the Medical Instruments & Supplies subindustry, Bioject Medical Technologies's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioject Medical Technologies's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioject Medical Technologies's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Bioject Medical Technologies's ROC (Joel Greenblatt) % falls into.



Bioject Medical Technologies ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2011 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.522 + 1.501 + 0.16) - (1.623 + 0.36 + 0.764)
=-0.564

Working Capital(Q: Sep. 2011 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.844 + 0.893 + 0.077) - (1.162 + 0.176 + 0.748)
=-0.272

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Bioject Medical Technologies for the quarter that ended in Sep. 2011 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2011 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2011  Q: Sep. 2011
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1.68/( ( (0.476 + max(-0.564, 0)) + (0.436 + max(-0.272, 0)) )/ 2 )
=1.68/( ( 0.476 + 0.436 )/ 2 )
=1.68/0.456
=368.42 %

Note: The EBIT data used here is four times the quarterly (Sep. 2011) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioject Medical Technologies  (OTCPK:BJCT) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Bioject Medical Technologies ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Bioject Medical Technologies's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioject Medical Technologies Business Description

Traded in Other Exchanges
N/A
Address
Bioject Medical Technologies Inc commenced operations in 1985 and is a developer and manufacturer of needle-free injection therapy systems (NFITS). The Companys long-term goal is to become supplier of needle-free injection systems to the pharmaceutical and biotechnology industries. It focused its business development efforts on new and existing licensing and supply agreements with pharmaceutical and biotechnology companies, as well as numerous research agreements that could guide to long-term agreements. The Companys pipeline of prospective new partnerships remains active. It is also actively pursuing additional opportunities both domestically and overseas as it expands its current product line. The Companys Biojector 2000 system (B2000) consists of two components: a hand-held, reusable jet injector and a sterile, single-use, disposable plastic syringe capable of delivering variable doses of medication up to 1.0 mL. Drug Reconstitution System - The needle-free drug reconstitution system allows for the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. Vitajet - The Vitajet is also composed of two components, a portable injector unit and a disposable syringe. It is smaller and lower in cost than other products in its needle-free offering. ZetaJet - The ZetaJet is Biojects latest advance in needle-free delivery systems. It consists of two components, the portable injector and an auto-disabling disposable syringe. The medical equipment market is very competitive. Bioject Medical Technologies has two patents: Biojector 2000 and Vitajet. The Companys products and manufacturing operations are subject to extensive government regulations, both in the U.S. and abroad. In the U.S., the Food and Drug Administration (FDA) administers the Federal Food, Drug and Cosmetic Act (FFDCA) and has adopted regulations to administer the FFDCA.
Executives
James C Gale director 152 W 57TH STREET, 19TH FLOOR, NEW YORK NY 10019
Sanders Morris Harris Inc/fa 10 percent owner, other: See General Remarks 600 TRAVIS, SUITE 5900, HOUSTON TX 77002
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Edward L Flynn director, 10 percent owner 211 SOMERVILLE ROAD RTE 202N, BEDMINISTER NJ 07921
Life Sciences Opportunities Fund Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Lof Partners Llc other: See general remarks 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Life Sciences Opportunities Fund Instittutional Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Randal D Chase director 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
J Michael Redmond officer: Sr. VP Bus Dev. 10 CANTERBURY ROAD, WINDHAM NH 03087
Elan Corp Plc 10 percent owner TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000
Elan International Services Ltd 10 percent owner C/O TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN L2 2
Elan Pharmaceutical Investments Ltd 10 percent owner 102 ST JAMES COURT, FIETSS SMITH FL BERM D0 9999999999
John P Gandolfo officer: CFO 62 TERRACE ROAD, WAYNE NJ 07470
Grace K Fey director 1210 CROMWELL ROAD, HALIFAX NOVA SCOTIA A5 B3H4L2

Bioject Medical Technologies Headlines

No Headlines